Nuvation Bio (NUVB) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- -$0.09
- Estimate
- -$0.10
- Surprise
- +12.4%
- Revenue (period 2026-09-30)
- $45.0M
- Score today
- 4.9/10
Revenue source: xbrl.
How the report landed
Nuvation Bio (NUVB) reported a narrower loss than forecast — adjusted EPS of -$0.09 against the -$0.10 estimate (a 12.4% beat on a still-unprofitable quarter).
Coverage in the report window
- B. Riley and RBC Adjust Nuvation Bio Price Targets — fiscal.ai, 2026-11-05
Where TrendMatrix's rating stands now
TrendMatrix currently rates NUVB Sell at 4.9/10; no pre/post engine snapshot brackets this report.
1 of the last 4 quarters beat the estimate; this quarter's +12.4% surprise compares with a +567.2% four-quarter average. Next scheduled report: 2027-03-02.
What argues against it
- Concentration risk — Product: IBTROZI (taletrectinib)
- Concentration risk — Counterparty: Daiichi Sankyo (in-license partner)
- DATA_ISSUE: analyst_target_implausible (raw $13.00 vs price $4.21 — ratio 3.1×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $4.21
- Price target
- $4.90
- Stop
- $3.91
- Upside to target
- +16.5%
Model outputs from TrendMatrix’s engine as of 2026-11-06 — shown for context, not personalized investment advice.
NUVB at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $1.47B
- P/E (fwd)
- -279.3
- 52-week range
- $4.04–$9.75
- Off 52-week high
- 56.9%
- RSI (14)
- 43
- Volume vs avg
- 0.30×
- Score today
- 4.9/10